Impact of Testosterone Solution 2% on Ejaculatory Dysfunction in Hypogonadal Men

J Sex Med. 2016 Aug;13(8):1220-6. doi: 10.1016/j.jsxm.2016.05.012.

Abstract

Introduction: Hypogonadism is defined as decreased testosterone levels in men. Hypogonadism can be accompanied by erectile, orgasmic, and ejaculatory dysfunction.

Aims: To evaluate whether treatment with testosterone solution 2% (testosterone) could improve ejaculatory function in a cohort of hypogonadal men.

Methods: Sexually active, hypogonadal men at least 18 years old (total testosterone < 300 ng/dL) were randomized to receive testosterone or placebo for 12 weeks.

Main outcome measures: Effects of testosterone on primary outcomes were evaluated using the International Index of Erectile Function (IIEF) and the Men's Sexual Health Questionnaire, Ejaculatory Dysfunction, Short Form (MSHQ-EjD-SF) questionnaires. Treatment differences were calculated using analysis of covariance.

Results: In total, 715 men (mean age = 55 years) were randomized to placebo (n = 357) or testosterone (n = 358). Most sexually active men who reported IIEF scores had some degree of erectile dysfunction (IIEF erectile function score < 26). Although ejaculatory function score (MSHQ-EjD-SF) improved in the testosterone group compared with placebo (P < .001), improvement on the "bother" item did not reach statistical significance. Treatment-related adverse events in the testosterone group affecting at least 1% of patients were increased hematocrit, upper respiratory tract infection, arthralgia, burning sensation, fatigue, increased prostate-specific antigen, erythema, and cough. Few patients in either treatment group developed at least one adverse event leading to discontinuation (testosterone = 1.98% vs placebo = 3.09%; P = .475).

Conclusion: Hypogonadal men receiving testosterone solution 2% therapy experience significantly greater improvement in ejaculatory function, compared with placebo, as assessed by the MSHQ-EjD-SF. However, improvement in "bother" was not statistically different between the two groups. Testosterone therapy was generally well tolerated.

Keywords: Ejaculatory Dysfunction; Erectile Dysfunction; Hypogonadism; Orgasmic Dysfunction; Testosterone.

Publication types

  • Multicenter Study
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Aged
  • Androgens / administration & dosage*
  • Drug Administration Schedule
  • Ejaculation / drug effects
  • Erectile Dysfunction / drug therapy
  • Humans
  • Hypogonadism / drug therapy*
  • Male
  • Men's Health
  • Middle Aged
  • Orgasm / drug effects
  • Penile Erection / drug effects
  • Prostate-Specific Antigen / metabolism
  • Sexual Behavior / physiology
  • Surveys and Questionnaires
  • Testosterone / administration & dosage*
  • Treatment Outcome

Substances

  • Androgens
  • Testosterone
  • Prostate-Specific Antigen